IDH1 and acute myeloid leukemia: In a phase 1 study, 60 patients with IDH1-mutated AML received ivosidenib with cytarabine and anthracycline (7 + 3) induction and consolidation, followed by maintenance ivosidenib until progression or allogeneic stem cell transplant [73].